ads

Pfizer Inks Two-Year Research Collaboration With BioRestorative Therapies - Shares Fractionally Lower

Pfizer Inks Two-Year Research Collaboration With BioRestorative Therapies - Shares Fractionally Lower

Pfizer Inc. (PFE) has signed a two-year agreement with BioRestorative Therapies, Inc. to study human brown adipose tissue and cell lines. The results of the study may be used by both companies. According to MArk Weinreb, CEO of BioRestorative Therapies Research into human brown fat to date has suggested that brown fat is correlated with the maintenance and regulation of metabolism. Ultimately, we will look to determine if our cell lines have utility in the treatment of obesity, which is responsible for many diseases, including type 2 diabetes. PFE shares are slightly lower in the pre-market, down 0.24%.

Pfizer Inks Two-Year Research Collaboration With BioRestorative Therapies - Shares Fractionally Lower